STRUCTURAL DAMAGE PROGRESSION IN PATIENTS TREATED WITH METHOTREXATE, BARICITINIB MONOTHERAPY OR BARICITINIB plus METHOTREXATE BASED ON THEIR LEVEL OF CLINICAL RESPONSE IN THE PHASE 3 RA-BEGIN STUDY
Van Der Heijde D, Durez P, Schett G, Naredo E, Ostergaard M, Meszaros G, Bello N, De La Torre I, Lopez-Romero P, Schlichting D, Nantz E, Fleischmann R (2017)
Publication Type: Conference contribution
Publication year: 2017
Journal
Book Volume: 76
Pages Range: 233-233
Authors with CRIS profile
Involved external institutions
Université Catholique de Louvain (UCL)
Belgium (BE)
Leiden University
Netherlands (NL)
Eli Lilly and Company
United States (USA) (US)
University of Texas Southwestern Medical Center (UT Southwestern)
United States (USA) (US)
Fundación Jiménez Díaz
Spain (ES)
Rigshospitalet
Denmark (DK)
Belgium (BE)
Leiden University
Netherlands (NL)
Eli Lilly and Company
United States (USA) (US)
University of Texas Southwestern Medical Center (UT Southwestern)
United States (USA) (US)
Fundación Jiménez Díaz
Spain (ES)
Rigshospitalet
Denmark (DK)
How to cite
APA:
Van Der Heijde, D., Durez, P., Schett, G., Naredo, E., Ostergaard, M., Meszaros, G.,... Fleischmann, R. (2017). STRUCTURAL DAMAGE PROGRESSION IN PATIENTS TREATED WITH METHOTREXATE, BARICITINIB MONOTHERAPY OR BARICITINIB plus METHOTREXATE BASED ON THEIR LEVEL OF CLINICAL RESPONSE IN THE PHASE 3 RA-BEGIN STUDY. (pp. 233-233).
MLA:
Van Der Heijde, D., et al. "STRUCTURAL DAMAGE PROGRESSION IN PATIENTS TREATED WITH METHOTREXATE, BARICITINIB MONOTHERAPY OR BARICITINIB plus METHOTREXATE BASED ON THEIR LEVEL OF CLINICAL RESPONSE IN THE PHASE 3 RA-BEGIN STUDY." 2017. 233-233.
BibTeX: Download